Drug Information
| Drug General Information | |||||
|---|---|---|---|---|---|
| Drug ID |
D0X6BV
|
||||
| Former ID |
DCL001036
|
||||
| Drug Name |
Vilazodone
|
||||
| Synonyms |
Vilazodone [INN]; Vilazodone (TN); 5-[4-[4-(5-cyano-1H-indol-3-yl)butyl]piperazin-1-yl]-1-benzofuran-2-carboxamide; 5-[4-[4-(5-cyano-1H-indol-3-yl)butyl]piperazin-1-yl]benzofuran-2-carboxamide
|
||||
| Drug Type |
Small molecular drug
|
||||
| Indication | Major depressive disorder [ICD9: 296.2, 296.3, 710.0; ICD10:F32, F33, M32] | Approved | [1], [2] | ||
| Company |
Genaissance and Merck KGaA
|
||||
| Structure |
|
Download2D MOL |
|||
| Formula |
C26H27N5O2
|
||||
| InChI |
InChI=1S/C26H27N5O2/c27-16-18-4-6-23-22(13-18)19(17-29-23)3-1-2-8-30-9-11-31(12-10-30)21-5-7-24-20(14-21)15-25(33-24)26(28)32/h4-7,13-15,17,29H,1-3,8-12H2,(H2,28,32)
|
||||
| InChIKey |
SGEGOXDYSFKCPT-UHFFFAOYSA-N
|
||||
| CAS Number |
CAS 163521-12-8
|
||||
| PubChem Compound ID | |||||
| PubChem Substance ID |
14930538, 23950818, 43529694, 76910791, 85210119, 93300539, 103455044, 104040116, 114787770, 124490438, 126681745, 129231444, 134339460, 135270095, 137083322, 137188808, 141233041, 152064163, 152258562, 160645967, 160647397, 160831434, 162011476, 162224429, 163094960, 163392752, 164045358, 164766116, 170501384, 172914663, 175268384, 175427083, 178103999, 186005325, 198993119, 204388973, 223393050, 223536020, 223660986, 224093528, 226949401, 242060090, 246074631, 249863492, 251875390, 251916863, 251918102, 251971270, 252067762, 252091522
|
||||
| SuperDrug ATC ID |
N06AX24
|
||||
| Target and Pathway | |||||
| Target(s) | Sodium-dependent serotonin transporter | Target Info | Modulator | [1] | |
| 5-hydroxytryptamine 1A receptor | Target Info | Modulator | [1] | ||
| KEGG Pathway | Serotonergic synapsehsa04024:cAMP signaling pathway | ||||
| Neuroactive ligand-receptor interaction | |||||
| Serotonergic synapse | |||||
| NetPath Pathway | TCR Signaling Pathway | ||||
| PANTHER Pathway | 5HT1 type receptor mediated signaling pathway | ||||
| 5HT2 type receptor mediated signaling pathway | |||||
| 5HT3 type receptor mediated signaling pathway | |||||
| 5HT4 type receptor mediated signaling pathwayP00026:Heterotrimeric G-protein signaling pathway-Gi alpha and Gs alpha mediated pathway | |||||
| Reactome | Serotonin receptors | ||||
| G alpha (i) signalling events | |||||
| WikiPathways | Monoamine Transport | ||||
| SIDS Susceptibility Pathways | |||||
| NRF2 pathway | |||||
| Synaptic Vesicle Pathway | |||||
| Serotonin Transporter ActivityWP722:Serotonin HTR1 Group and FOS Pathway | |||||
| Monoamine GPCRs | |||||
| GPCRs, Class A Rhodopsin-like | |||||
| GPCR ligand binding | |||||
| GPCR downstream signaling | |||||
| References | |||||
| REF 1 | 2011 FDA drug approvals. Nat Rev Drug Discov. 2012 Feb 1;11(2):91-4. | ||||
| REF 2 | (http://www.guidetopharmacology.org/) Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 7427). | ||||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.